Benchmark Response ( BMR ) Values for In Vivo Mutagenicity Endpoints
Environmental and Molecular Mutagenesis · 2025
DOI: 10.1002/em.70006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental and Molecular Mutagenesis, 2025. Verfasst von Paul A White und 8 weiteren Autor:innen. Beteiligte Einrichtung: Environmental Health Science and Research Bureau, Environmental and Radiation Health Sciences Directorate, Health Canada, Ottawa, Canada. Hauptthemen laut MEDLINE: Benchmarking, Mutagens, Endpoint Determination. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Rijksinstituut voor Volksgezondheid en Milieu, Health Canada.
Abstract (Originalsprache)
The benchmark dose (BMD) approach constitutes the most effective and pragmatic strategy for the derivation of a point of departure (PoD) for comparative potency analysis, risk assessment, and regulatory decision‐making. There is considerable controversy regarding the most appropriate benchmark response (BMR) for genotoxicity endpoints. This work employed the Slob (2017) Effect Size (ES) theory to define robust BMR values for the in vivo transgenic rodent (TGR) and Pig‐a mutagenicity endpoints. An extensive database of dose–response data was prepared and curated; BMD analyses were used to determine endpoint‐specific maxima (i.e., parameter c ) and within‐group variance (i.e., var ). Detailed analyses investigated the dependence of var on experimental factors such as tissue, administration route, treatment duration, and post‐exposure tissue sampling time. The overall lack of influence of these experimental factors on var permitted the determination of typical values for the endpoints investigated. Typical var for the TGR endpoint is 0.19; the value for the Pig‐a endpoint is 0.29. Endpoint‐specific var values were used to calculate endpoint‐specific BMR values; the values are 47% for TGR and 60% for Pig‐a . Endpoint‐specific BMR values were also calculated using the trimmed distribution of study‐specific standard deviation (SD) values for concurrent controls. Those analyses yielded endpoint‐specific BMR values for the TGR and Pig‐a endpoints of 33% and 58%, respectively. Considering the results obtained, and the in vivo genetic toxicity BMR values noted in the literature, we recommend a BMR of 50% for in vivo mutagenicity endpoints. The value can be employed to interpret mutagenicity dose–response data in a risk assessment context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Environmental Health Science and Research Bureau, Environmental and Radiation Health Sciences Directorate, Health Canada, Ottawa, Canada.
- Centre for Prevention, Lifestyle and Health, RIVM (National Institute for Public Health and the Environment), Bilthoven, the Netherlands.
- Department of Biology, University of Ottawa, Ottawa, Canada.
- Swansea University Medical School, Swansea University, Swansea, UK.
- Pharmaceutical Sciences, pRED Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
- Bureau of Chemical Safety, Food and Nutrition Directorate, Health Canada, Ottawa, Canada.
ORCID-Profile: George E Johnson, Andreas Zeller
Förderung
- Rijksinstituut voor Volksgezondheid en Milieu
- Health Canada
Zitieren
APA
White, P. A., Chen, G., Chepelev, N., Bell, M. A., Gallant, L. R., Johnson, G. E., Zeller, A., Beal, M. A., & Long, A. S. (2025). Benchmark Response ( BMR ) Values for In Vivo Mutagenicity Endpoints. Environmental and Molecular Mutagenesis. https://doi.org/10.1002/em.70006
Vancouver
White PA, Chen G, Chepelev N, Bell MA, Gallant LR, Johnson GE, et al. Benchmark Response ( BMR ) Values for In Vivo Mutagenicity Endpoints. Environmental and Molecular Mutagenesis. 2025. doi:10.1002/em.70006
BibTeX
@article{White2025,
author = {White, Paul A and Chen, Guangchao and Chepelev, Nikolai and Bell, Madison A and Gallant, Lauren R and Johnson, George E and Zeller, Andreas and Beal, Marc A and Long, Alexandra S},
title = {Benchmark Response ( BMR ) Values for In Vivo Mutagenicity Endpoints},
journal = {Environmental and Molecular Mutagenesis},
year = {2025},
doi = {10.1002/em.70006}
}
EUVIMED